Abstract 310P
Background
Leukoplakia is a oral pathology characterized by an increased risk for malignant transformation. Histopathology of leukoplakia can disclose hyperkeratosis with dysplasia or carcinoma or hyperkeratosis or parakeratosis without dysplasia. Existence of the different treatment options not decrease the the rates of recurrence up to 35%.
Methods
Totally 40 patients with OL (homogenous type - 35 cases; verrucous type - 4 case; erythroleukoplakia - one case) were recruited for the study. In a period September 2017 – may 2019 all the patients were screened, and only those patients with clinically, and histologically proven OL was included under the study. All the patients had the history of using tobacco in smoking or smokeless form (Nasvay). 1470 nm diode laser ablation was done under 5- ALA induced spectroscopy. In case of detection a pathological fluorescence after the session treatment was accompanied with PDT treatment. 10% ALA emulsion (0.1 g of 99.9% ALA powder in 1 ml liquid paraffin) was used freshly just before the start of the therapy to avoid deterioration of the emulsion on contact with light. Diode lamp (Vostok -1, Uzbekistan) with power - 5 W, wavelength -630 ± 5 nm was used as the light source. Total dose delivered per session was 100 J/cm 2 . The therapy was performed in a one session. All patients were recalled at 4 weeks after completion of the last session of modified therapy. Lesion response was characterized as follows: Complete response (CR), ; partial response (PR), reduction at least 20% in diameter; no response (NR). The patients were followed-up for a period of 1 year.
Results
One month (4 weeks) after 1470 nm diode laser ablation + ALA-PDT, the response was evaluated based on clinical examination. CR was obtained in 35 out of 40 patients; PR in 5 out of 40 patients; and NR no patient. During the follow-up, no changes in the clinical appearance of the treated lesions were recorded. There was no recurrence of the lesion noted in CR cases. During the incubation period of 3 h after ALA application, the patients did not have any adverse effect in the form of pain, redness or discomfort. Patients did not have any other side effects.
Conclusions
Our observations suggest that topical ALA mediated PDT with laser ablation is a promising means of treating OL.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tashkent medical academy.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
528P - High-biologically effective dose radiotherapy may improve local control of small cell lung cancer patients with brain metastases: A propensity-matching analysis
Presenter: Qingyang Zhuang
Session: Poster display session
Resources:
Abstract
530P - Prognostic value of C-reactive protein, albumin and C-reactive protein to albumin ratio in small cell lung cancer: A meta-analysis
Presenter: Carla Emille Barbon
Session: Poster display session
Resources:
Abstract
531TiP - CANOPY-A: A phase III, placebo-controlled study of canakinumab as adjuvant therapy in patients (pts) with surgically resected NSCLC
Presenter: Byoung Chul Cho
Session: Poster display session
Resources:
Abstract
532TiP - CANOPY-1: A phase III, placebo-controlled study of pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) with/without canakinumab in untreated patients (pts) with stage IIIB/IIIC-IV NSCLC
Presenter: Daniel Shao Weng Tan
Session: Poster display session
Resources:
Abstract
533TiP - CANOPY-2: A phase III, placebo-controlled study of canakinumab with or without docetaxel in patients (pts) with NSCLC previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy (Ctx)
Presenter: Darren Lim
Session: Poster display session
Resources:
Abstract
534TiP - A randomized phase III study of carboplatin plus nab-paclitaxel with or without nintedanib for NSCLC with IPF (J-SONIC)
Presenter: Kohei Otsubo
Session: Poster display session
Resources:
Abstract
535TiP - Phase II study of atezolizumab for pretreated advanced / recurrent non-small cell lung cancer with idiopathic interstitial pneumonia (TORG1936 / AMBITIOUS study)
Presenter: Satoshi Ikeda
Session: Poster display session
Resources:
Abstract
536TiP - INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study
Presenter: James C-H Yang
Session: Poster display session
Resources:
Abstract
YO8 - Carcinosarcoma of the Breast in a Filipino Female: A Case Report
Presenter: Ma. Angelle Lalaine Dantes
Session: Poster display session
Resources:
Abstract
YO9 - Small Malignant Phyllodes Tumor of the Breast with Metastases to the Lung and Bone
Presenter: Gusti Harti
Session: Poster display session
Resources:
Abstract